{
}
UBS has raised its price target for Bilfinger from €70 to €86, indicating a 23% upside potential due to strong cash generation, stable demand in key sectors, and solid quarterly results. Despite a 67% year-to-date gain and a current price of €77.55, UBS believes the stock is not fully valued, setting high expectations for future performance. The upcoming quarterly figures will be crucial in determining if Bilfinger can meet these forecasts.
UBS has increased its price target for Bilfinger from 70 to 86 euros while maintaining a "Buy" rating. Analyst Olivier Calvet noted that the industrial services provider is on a clear path to generate more cash, supported by favorable end markets, with potential not yet fully reflected in the share price.
UBS has increased its price target for Bilfinger from 70 to 86 euros while maintaining a "Buy" rating. Analyst Olivier Calvet noted that the industrial services provider is on a clear path to generate more cash, supported by favorable end markets, with potential not yet fully reflected in the share price.
UBS has increased its price target for Bilfinger from 70 to 86 euros while maintaining a "Buy" rating. Analyst Olivier Calvet noted that the industrial services provider is on a clear path to generate more cash, supported by favorable end markets, with potential not yet fully reflected in the share price.
UBS has increased its price target for Bilfinger from 70 to 86 euros while maintaining a "Buy" rating. Analyst Olivier Calvet noted that the industrial services provider is on a clear path to generate more cash, supported by favorable end markets, with potential not yet fully reflected in the share price.
UBS has maintained a "Buy" rating for CTS Eventim, setting a target price of 116 euros. The ticket marketer surpassed revenue expectations but fell short in operating profit (EBITDA), according to analyst Olivier Calvet's assessment of the quarterly figures.
UBS has upgraded its price target for Schott Pharma from €28.20 to €29.20 while maintaining a "buy" rating. The pharmaceutical supplier reported a strong quarter, although a cautious outlook for 2025 has tempered expectations, according to analyst Olivier Calvet.
UBS has maintained a "Buy" rating for CTS Eventim, setting a target price of 116 euros. Analyst Olivier Calvet noted that investors are likely anticipating strong comparative figures ahead of the ticket marketer's first-quarter results, with potential for positive surprises.
UBS has maintained a 'Buy' rating for CTS Eventim, setting a target price of 116 euros. Analyst Olivier Calvet noted that investors are likely anticipating strong comparative figures ahead of the ticket marketer's first-quarter results, with potential for positive surprises.
UBS has maintained its "Buy" rating for Schott Pharma, setting a target price of 28.20 euros after the release of strong quarterly figures. Analyst Olivier Calvet noted that the final key figures confirmed the robust preliminary data.
Olivier Calvet
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS Raises Bilfinger Price Target Signaling Strong Growth Potential Ahead
06:40 24.05.2025
UBS Increases Bilfinger Price Target to 86 Euros Maintains Buy Rating
10:05 23.05.2025
UBS Raises Bilfinger Price Target to 86 Euros Maintains Buy Rating
09:37 23.05.2025
UBS Raises Bilfinger Price Target to 86 Euros Maintains Buy Rating
08:07 23.05.2025
UBS Raises Bilfinger Price Target to 86 Euros Maintains Buy Rating
08:06 23.05.2025
UBS Maintains Buy Rating on CTS Eventim with Target Price of 116 Euros
13:52 22.05.2025
UBS raises Schott Pharma price target to 29.20 euros maintains buy rating
13:54 20.05.2025
ubs maintains buy rating for cts eventim with target price of 116 euros
10:17 19.05.2025
ubs maintains buy rating for cts eventim with target price of 116 euros
09:04 19.05.2025
UBS maintains buy rating for Schott Pharma with target price of 28.20 euros
15:07 15.05.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: